HOME > TOP STORIES

TOP STORIES

BUSINESS Ono and Germany’s Merck Enter into License Agreements to Boost Priority Fields

October 5, 2011
ORGANIZATION Leading Biotech Clusters in Osaka, Munich Sign Partnership Agreement

October 5, 2011
REGULATORY FPMAJ States Difficulty in Identifying Anticancer Drugs in Terms of Adverse Reactions

October 4, 2011
BUSINESS Mochida’s New 3-Year Business Plan Aims for Sales of ¥100 Bil. in FY2013

October 4, 2011
BUSINESS Takeda Completes Acquisition of Nycomed, Global Rx Sales Ranking Up to 12th

October 3, 2011
ORGANIZATION Takeda “Will Be Able to Get Through” Power Shortages: Mr Hasegawa

October 3, 2011
ORGANIZATION “Permanent Introduction of Premium for New Drug Development Premature”: CSIMC Member Adachi

September 30, 2011
BUSINESS MS Pharma Forms Strategic Alliance with Korean Company in Biosimilars

September 30, 2011
BUSINESS Takeda President Hasegawa Eyes Joint Research with Chinese Companies

September 29, 2011
REGULATORY CSIMC’s Committee to Assess Premium for New Drug Development Based on Results of Market Price Survey

September 29, 2011
BUSINESS MTPC to Start PIII Trial for Telaprevir in China Early 2012

September 29, 2011
ORGANIZATION JPMA Head Says Industry Will Support Infrastructure Development for Innovative Drug Discovery

September 28, 2011
BUSINESS Astellas Pharma Debuts on DJSI Asia Pacific Index

September 28, 2011
BUSINESS BMS to File for Apixaban for Stroke Prevention in Japan, US, and Europe Before Year-end

September 27, 2011
ORGANIZATION Continuation of Premium for New Drug Development to Depend on Effects on Drug Lag, Drug Development: Mr Shirakawa of Kenporen

September 26, 2011
REGULATORY 6 APIs/10 Products Including EpiPen Added to NHI Price List

September 22, 2011
BUSINESS Novartis Grows 7% Driven by New Products: President Mitani

September 22, 2011
BUSINESS Kaken President Onuma Targets ¥20 Billion in Operating Profits in 2015

September 21, 2011
ORGANIZATION FPMAJ Seeks Improved System for Orphan Drug Development, Request to Be Submitted Soon to Health Minister

September 20, 2011
REGULATORY HSC Subcommittee Agrees on Need for New System to Promote Access to Unapproved Drugs

September 20, 2011

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Pharma Renews Call to Scrap “Spillover,” “Huge-Seller” Rules as FY2026 Talks Enter Final Stretch

By Ken Yoshino

Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…

COMMENTARY

FY2026 Reform Debate for Drug Pricing Nears the Finish Line, Balance Needed

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

COLUMN

AI in HR: Navigating the Ethical Minefield

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…